Proven, Predictive, Published
- Performance Data
- Product Highlights
Heart disease encompasses a wide range of conditions that can be a result of genetics, physiologic, and metabolic disorders as well as adverse drug reactions. The availability of human cell models that could be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures for heart disease. Derived from induced pluripotent stem cells (iPSCs), iCell® Cardiomyocytes from FUJIFILM Cellular Dynamics, Inc. (FCDI), enable a wide range of applications spanning disease research, drug discovery, safety and toxicity testing, and regenerative medicine.
- Industry Standard With the most peer-reviewed publications and supported application protocols, iCell Cardiomyocytes are the in vitro model of choice.
- Reproducible Research High purity and rigorous quality control ensure the same performance and reproducible results with every batch of iCell Cardiomyocytes.
- Human Relevance iCell Cardiomyocytes recapitulate healthy human cardiac biology and function and express relevant targets and pathways for heart disease research.
- Diverse Availability iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.
iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.
|iCell Cardiomyocytes, 01434||iCell Cardiomyocytes, 11713|
|Age Group (at collection)||<18||35 - 39|
|Reprogramming Method||Retroviral Transduction||Episomal|
- Cardiotoxicity Assessment
Retrospective analyses were leveraged to uncover previously undetected mechanisms of drug-induced cardiotoxicity and provide relevant data in support of Investigational New Drug (IND) applications (Talbert et al., 2014; Cameron et al., 2013; Doherty et al., 2013; Rana et al., 2012; Cohen et al., 2011).
- Arrhythmia Testing
iCell Cardiomyocytes are changing regulatory paradigms by providing a highly predictive model for detecting drug-induced arrhythmia (Guo et al., 2018).
- Cardiac Hypertrophy Studies
iCell Cardiomyocytes can detect known and novel biomarkers and identify new targets for drug discovery and therapeutics research (Jones et al., 2015, Drawnel et al., 2014; Arrarwal et al., 2014; Traister et al., 2014;Zhi et al., 2012).
- Calcium Signaling
Simultaneously assess effects on electrical and calcium signals measurements using iCell Cardiomyocytes with FDSS ( Bedut et al., 2016) or FLIPR platforms.
- Regenerative Medicine
iCell Cardiomyocytes are compatible with bioengineered, implantable scaffolds used as a model for heart repair following myocardial infarction (Richards et al., 2017;Beauchamp et al., 2015; Holt-Casper et al., 2015; Lancaster et al., 2012).
Application protocols for iCell Cardiomyocytes have been optimized for cells derived from the genetic background 01434. A subset of these protocols have been tested with cells derived from the genetic background 11713 and require no modification. Additional applications have not yet been tested using 11713. Protocols supported for both iCell Cardiomyocytes, 01434 and 11713:
- Field Potential Detection on the Maestro Multielectrode Array
- Impedance Detection with xCELLigence RTCA Cardio System
- Intracellular Calcium Flux Detection on the FLIPR Tetra System
- Immunofluorescent Labeling
- Extracting Total RNA
Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, Wang J, Zhai J, DeGeorge J, Sannajust F. (2016) Interaction between Amiodarone and Hepatitis-C Virus Nucleotide Inhibitors in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes and HEK-293 Cav1.2 Over-expressing Cells. Toxicol Appl Pharmacol 308:66-76.
Necela B, Axenfeld B, Serie D, Kachergus J, Perez E, Thompson E, Norton N. (2017) The Antineoplastic Drug, Trastuzumab, Dysregulates Metabolism in iPSC-derived Cardiomyocytes. Clin Transl Med 6(1):5.
Huo J, Kamalakar A, Yang X, Word B, Stockbridge N, Lyn-Cook B, Pang L. (2017) Evaluation of Batch Variations in Induced Pluripotent Stem Cell-derived Human Cardiomyocytes from 2 Major Suppliers. Toxicol Sci 156(1):25-38.
Zeng H, Balasubramanian B, Lagrutta A, Sannajust. (2018) Response of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes to Several Pharmacological Agents When Intrinsic Syncytial Pacing Is Overcome by Acute External Stimulation. J Pharmacol Toxicol Methods (91):18-26.
Schocken D, Stohlman J, Vicente J, Chan D, Patel D, Matta MK, Patel V, Brock M, Millard D, Ross J, Strauss DG, Blinova K. (2018) Comparative Analysis of Media Effects on Human Induced Pluripotent Stem Cell-derived Cardiomyocytes in Proarrhythmia Risk Assessment. J Pharmacol Toxicol Methods (90):39-47.
Bedut S, Seminatore-Nole C, Lamamy V, Caignard S, Boutin JA, Nosjean O, Stephan JP, Coge F. (2016) High-throughput Drug Profiling with Voltage- and Calcium-sensitive Fluorescent Probes in Human iPSC-derived Cardiomyocytes. Am J Physiol Heart Circ Physiol 311(1):H44-53.